dc.contributor.author | Solli, Kristin Klemmetsby | |
dc.contributor.author | Kunøe, Nikolaj | |
dc.contributor.author | Latif, Zill-E-Huma | |
dc.contributor.author | Haase, Kamni Sharma | |
dc.contributor.author | Opheim, Arild | |
dc.contributor.author | Krajci, Peter | |
dc.contributor.author | Gaulen, Zhanna | |
dc.contributor.author | Saltyte Benth, Jurate | |
dc.contributor.author | Tanum, Lars Håkon Reiestad | |
dc.date.accessioned | 2021-04-19T09:07:40Z | |
dc.date.available | 2021-04-19T09:07:40Z | |
dc.date.created | 2019-07-30T10:18:58Z | |
dc.date.issued | 2019 | |
dc.Published | European Addiction Research. 2019, 25 (6), 1-7. | |
dc.identifier.issn | 1022-6877 | |
dc.identifier.uri | https://hdl.handle.net/11250/2738289 | |
dc.description.abstract | Background and objective: Opioid maintenance treatment (OMT) is highly available in Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This study was aimed at examining if availability of extended-release naltrexone (XR-NTX) could attract individuals who for different reasons were not enrolled in an OMT program. Methods: In a Norwegian clinical study, n = 117 opioid-dependent adults volunteered to receive XR-NTX in a 9-month period, as an extension of a previous randomized clinical trial. Results: Before study inclusion, 40.2% (n = 47) of the study participants were not enrolled in OMT while the remainder were recruited from OMT. Participants not enrolled in OMT displayed more ongoing severe addiction-related problems such as heroin use (p = 0.002), but displayed a higher retention in treatment in the 9-month extension study (p = 0.048 for log-rank test) than participants enrolled in OMT. Conclusion: Availability of XR-NTX attracted opioid-dependent individuals not previously enrolled in OMT. While OMT may be perceived as a burden with regard to daily intake and control measures, one-monthly injections with XR-NTX may be perceived favourable, offering more freedom to the patients, not having addictive properties, and potentially reducing heroin craving. We suggest that an introduction of XR-NTX in Europe may increase the number of opioid-dependent individuals in treatment. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Karger | en_US |
dc.title | Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: Extension of a randomized clinical trial | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | acceptedVersion | en_US |
dc.rights.holder | Copyright 2019 S. Karger AG, Basel | en_US |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1159/000501931 | |
dc.identifier.cristin | 1713146 | |
dc.source.journal | European Addiction Research | en_US |
dc.source.40 | 25 | |
dc.source.14 | 6 | |
dc.source.pagenumber | 303–309 | en_US |
dc.identifier.citation | European Addiction Research. 2019, 25 (6), 303-309 | en_US |
dc.source.volume | 25 | en_US |
dc.source.issue | 6 | en_US |